Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4)
Rubino D, Abrahamsson N, Davies M, et al.
JAMA, 2021 · n = 902
Key finding
Continued semaglutide produced further weight loss (-7.9%) while switching to placebo resulted in weight regain (+6.9%), demonstrating need for ongoing treatment.
Summary
Withdrawal study showing participants who switched from semaglutide to placebo regained weight, while those continuing lost additional weight.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on Semaglutide
Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)
New England Journal of Medicine · 2023 · Human RCT
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)
New England Journal of Medicine · 2023 · Human RCT
Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)
Nature Medicine · 2022 · Human RCT
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8)
JAMA · 2022 · Human RCT
STEP 3: Semaglutide for Weight Management in Severe Obesity
New England Journal of Medicine · 2022 · Human RCT